Endometrial Cancer

>

Latest News

FDA Grants Priority Review to Pembrolizumab/Chemo in Endometrial Cancer | Image Credit: © freshidea - stock.adobe.com.
FDA Grants Priority Review to Pembrolizumab/Chemo in Endometrial Cancer

February 20th 2024

Data from the phase 3 NRG-GY018 trial support the supplemental biologics license application for pembrolizumab plus chemotherapy as a treatment for those with primary advanced or recurrent endometrial cancer.

Data from part 2 of the phase 3 RUBY trial support the use of dostarlimab as a backbone for immunotherapy-based combinations in patients with primary advanced or recurrent endometrial cancer.
Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer

December 20th 2023

The European approval for dostarlimab and chemotherapy for dMMR/MSI-H, primary advanced or recurrent endometrial cancer is based on data from part 1 of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.
Dostarlimab/Chemo Receives EU Approval for dMMR/MSI-H Endometrial Cancer

December 13th 2023

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.
Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden

November 27th 2023

Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer
Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer

November 26th 2023

More News